Literature DB >> 24951037

Fecal-based colorectal cancer screening among the uninsured in northern Manhattan.

Grace Clarke Hillyer1, Karen M Schmitt2, Daniel E Freedberg3, Rachel A Kramer4, Yin Su4, Richard M Rosenberg3, Alfred I Neugut5.   

Abstract

BACKGROUND: Colorectal cancer (CRC) screening reduces CRC mortality; however, for many reasons, uninsured individuals are less likely to utilize CRC screening tests.
PURPOSE: To compare CRC screening behaviors and outcomes with guaiac fecal occult blood testing (gFOBT) from 1998 to 2006 and fecal immunochemical testing (FIT) from 2006 to 2010 in a community-based program serving uninsured patients in northern Manhattan.
METHODS: In 2013, we conducted a retrospective record review of individuals aged ≥50 years who received fecal-based CRC screening at the Northern Manhattan Cancer Screening Partnership between 1998 and 2010. Included were those with household income ≤250% of the federal poverty level, no medical insurance coverage, and who were not up to date with CRC screening. We assessed screening positivity rate, positive predictive value, differences in the use of diagnostic colonoscopy, colonoscopic findings, and adenoma detection rates for gFOBT versus FIT.
RESULTS: In total, 7,710 patients completed CRC screenings (4,951 gFOBT and 2,759 FIT). The majority were female, Hispanic, foreign born, and young at age of first screening. Compared to gFOBT, FIT detected twice as many positive tests (3.2% vs 1.5%, p≤0.001) and had a higher adenoma detection rate (18.2 vs 11.8, p=0.002).
CONCLUSIONS: The improved positivity and adenoma detection rates with greater number of screening tests over time favor the use of FIT over gFOBT for colorectal screening among uninsured populations in northern Manhattan.
Copyright © 2014 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24951037      PMCID: PMC4127996          DOI: 10.1016/j.amepre.2014.03.011

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  31 in total

1.  Cancer screening - United States, 2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-01-27       Impact factor: 17.586

2.  Feasibility and efficacy of pairing fecal immunochemical testing with mammography for increasing colorectal cancer screening among uninsured Latinas in northern Manhattan.

Authors:  Grace Clarke Hillyer; Charles E Basch; Karen M Schmitt; Alfred I Neugut
Journal:  Prev Med       Date:  2011-06-22       Impact factor: 4.018

3.  Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening.

Authors:  Aafke H C van Roon; S Luuk Goede; Marjolein van Ballegooijen; Anneke J van Vuuren; Caspar W N Looman; Katharina Biermann; Jacqueline C I Y Reijerink; Hans 't Mannetje; Alexandra C M van der Togt; J Dik F Habbema; Monique E van Leerdam; Ernst J Kuipers
Journal:  Gut       Date:  2012-03-02       Impact factor: 23.059

4.  A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study.

Authors:  Zohar Levi; Shlomo Birkenfeld; Alex Vilkin; Micha Bar-Chana; Irena Lifshitz; Miri Chared; Eran Maoz; Yaron Niv
Journal:  Int J Cancer       Date:  2011-05-15       Impact factor: 7.396

5.  Surveillance of screening-detected cancers (colon and rectum, breast, and cervix) - United States, 2004-2006.

Authors:  S Jane Henley; Jessica B King; Robert R German; Lisa C Richardson; Marcus Plescia
Journal:  MMWR Surveill Summ       Date:  2010-11-26

6.  Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer.

Authors:  S R Cole; G P Young
Journal:  Med J Aust       Date:  2001-08-20       Impact factor: 7.738

7.  Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.

Authors:  James E Allison; Lori C Sakoda; Theodore R Levin; Jo P Tucker; Irene S Tekawa; Thomas Cuff; Mary Pat Pauly; Lyle Shlager; Albert M Palitz; Wei K Zhao; J Sanford Schwartz; David F Ransohoff; Joseph V Selby
Journal:  J Natl Cancer Inst       Date:  2007-09-25       Impact factor: 13.506

8.  Moving forward: using the experience of the CDCs' Colorectal Cancer Screening Demonstration Program to guide future colorectal cancer programming efforts.

Authors:  Laura C Seeff; Amy DeGroff; Djenaba A Joseph; Janet Royalty; Florence K L Tangka; Marion R Nadel; Marcus Plescia
Journal:  Cancer       Date:  2013-08-01       Impact factor: 6.860

9.  Closing the loop: physician communication with diabetic patients who have low health literacy.

Authors:  Dean Schillinger; John Piette; Kevin Grumbach; Frances Wang; Clifford Wilson; Carolyn Daher; Krishelle Leong-Grotz; Cesar Castro; Andrew B Bindman
Journal:  Arch Intern Med       Date:  2003-01-13

10.  As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia.

Authors:  M Parekh; A M Fendrick; U Ladabaum
Journal:  Aliment Pharmacol Ther       Date:  2008-01-29       Impact factor: 8.171

View more
  5 in total

1.  Timeliness of Colonoscopy After Abnormal Fecal Test Results in a Safety Net Practice.

Authors:  Ann Oluloro; Amanda F Petrik; Ann Turner; Tanya Kapka; Jennifer Rivelli; Patricia A Carney; Somnath Saha; Gloria D Coronado
Journal:  J Community Health       Date:  2016-08

2.  Where does it FIT? The roles of fecal testing and colonoscopy in colorectal cancer screening.

Authors:  Grace Clarke Hillyer; Alfred I Neugut
Journal:  Cancer       Date:  2015-05-20       Impact factor: 6.860

3.  Latinas' Colorectal Cancer Screening Knowledge, Barriers to Receipt, and Feasibility of Home-Based Fecal Immunochemical Testing.

Authors:  Echo L Warner; Julia Bodson; Ryan Mooney; Djin Lai; N Jewel Samadder; Deanna Kepka
Journal:  J Immigr Minor Health       Date:  2018-08

4.  Improving Adenoma Detection Rates: The Role of the Fecal Immunochemical Test.

Authors:  Eugene C Nwankwo; Jefferson Lines; Sahiba Trehan; Michelle Marsh; Amit Trehan; Kuldip Banwait; Srinivas Pathapati; Subhasis Misra; Izi Obokhare
Journal:  Cureus       Date:  2021-04-09

5.  The fecal immunochemical test (fit): Selected aspects regarding its effectiveness for colorectal cancer screening in Quebec City.

Authors:  Mireille Caron; Gabriel Lamarre; Philippe Grégoire; David Simonyan; Nathalie Laflamme
Journal:  Prev Med Rep       Date:  2018-08-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.